Cinfa Biotech to share its experience on the development of biosimilars at three upcoming conferences

Pamplona, Spain, April 7, 2016

Cinfa Biotech S.L., the biosimilars company of Infarco group, today announced that it will present at the following conferences:


DIA 28th Annual EuroMeeting 2016

Date: April 7, 2016, 12:40 pm CEST (11:40 am BST)
Venue: Congress Center Hamburg (CCH), Hamburg, Germany
Dr Karsten Roth, Director Clinical Operations of Cinfa Biotech GmbH, will present a poster on “Clinical Development Strategies for Biosimilars – A Mid-Size Pharma Perspective”
http://www.diaglobal.org/Flagship/EuroMeeting-2016


AIQS 3a. Jornada de Biosimilares 2016

Date: April 12, 2016, 12:10 pm CEST (11:10 am BST)
Venue: Institut Quimic de Sarria, Barcelona, Spain
Dr Ruediger Jankowsky, Managing Director of Cinfa Biotech GmbH, will speak about “Overcoming the challenges of biosimilar development as a mid-size player”.
http://www.quimicaysociedad.org/wp-content/uploads/programa-3a-jornadabiosimilares-realidades-y-oportunidades-12-abril-2016.pdf


EBG Biosimilars 2016 – 14th European Biosimilars Group Conference

Date: April 28, 2016, 17:00 pm CEST (16:00 pm BST)
Venue: Grange Tower Bridge Hotel, London, England
Dr Ruediger Jankowsky, Managing Director of Cinfa Biotech GmbH, will participate in the panel discussion on “Increasing Access to Biosimilar Medicines in the Hospital Settings around Europe”
http://www.egaevents.org/bios/


About Cinfa Biotech

Cinfa Biotech is headquartered in Pamplona, Spain, with offices in Munich, Germany. The company was founded in 2013 and received an investment from its parent company Infarco to create a pipeline of biosimilar drugs to address the growing need for affordable therapies based on proven science, quality, safety and efficacy. A complete team of experts with decades of in-depth experience is developing biosimilars for a range of indications.

The first product candidate in clinical development is B12019, a biosimilar version of Neulasta® (pegfilgrastim). The ommercialisation models will be customised to the needs of partners and markets. Product development, clinical studies, manufacturing and quality control at Cinfa Biotech are conducted in Europe according to the highest European standards.


About Infarco – parent company of Cinfa Biotech

Infarco, the parent company of Cinfa Biotech, holds a portfolio of pharmaceutical companies. With 50 years’ experience, Infarco represents the successful professional approach of a group of pharmacists to recover the central role of pharmacists in the
pharmaceutical industry. The Company today employs over 1,200 people and reinvests an average of 90% of its annual profits in its portfolio companies, thereby driving their development and innovation.

For more information please visit: www.cinfabiotech.com


For press enquiries:


MC Services AG

Julia von Hummel, Kaja Skorka

Phone: +49 89 210 228-0

Email: Julia.vonHummel[at]mc-services.eu

Email: kaja.skorka[at]mc-services.eu


Shaun Brown

Phone: +44-20-71485998

Email: shaun.brown[at]mc-services.eu


Download as PDF